8^th Euro Global Diabetes Summit and Medicare Expo November 03-05, 2015 Valencia, Spain

Emilio Herrera is PhD from Complutense University (Madrid), Emeritus professor of Biochemistry and Molecular Biology at Faculties of Pharmacy and Medicine, University San Pablo-CEU in Madrid, Spain and Doctor Honoris causa in Medicine by Lund University (Sweden). He carried out his postdoctoral studies in Harvard University and Northwestern University Medical Schools. He has 282 peer-reviewed papers with IF (total IF by JCR-2009, 755.20) and 77 book chapters, having a h-index of 37 and has directed 49 PhD thesis.

Role of maternal lipids on neonatal body weight under healthy and gestational diabetic conditions

Dr. Collino was born in Italy, on 19th January 1973. Degree in Pharmaceutical Chemistry and Technology at the University of Turin, Faculty of Pharmacy, March 1998: summa cum laude. Ph. D. in “Pharmacology and Toxicology” at the University of Turin, 1998 – 2002. Visiting Scientist at The William Harvey Research Institute, Centre for Experimental Medicine, Nephrology & Critical Care, Barts and The London, Queen Mary\s School of Medicine and Dentistry, London (UK) in the years 2003-2004. Since 2002 Assistant Professor of Pharmacology, Faculty of Pharmacy, University of Turin. Member of the Italian Society of Pharmacology, the European Biomedical Research Association. , British Pharmacological Society, European Shock Society

His research activity is focused mainly on the investigation of innovative pharmacological strategies for metabolic disorders and the related cardiovascular complications

Sebastian studied clinical medicine at “Iuliu Hatieganu” Medical School, Cluj-Napoca, Romania and trained as a junior doctor in Nephrology and Dialysis before moving to USA where he obtained a PhD from the University of Nebraska-Lincoln in 2004.This was followed by postdoctoral training at Duke University Medical Center (North Carolina, USA) where he became interested in studying the connections between alternative splicing and cancer. Using fluorescent splicing reporters that recapitulate in vivo the alternative splicing of fibroblast growth factor 2 and are able to follow epithelial-mesenchymal transitions he discovered unusual plasticity in prostate cancer cells in animal models. This was further followed by studies of circulating tumour cells from patients showing that the same plasticity is associated with aggressive prostate and breast cancer behavior.Since moving to the University of Bristol in 2008 he continued to study alternative splicing in vivo, switching the focus towards the importance of VEGF splice isoforms in cancer as well as kidney diseases.

My main research interests include the study of alternative splicing in vivo, coordinated regulation of alternative splicing in physiology and disease as well as manipulation of splice isoforms choice for therapeutic goals. Alternative splicing is the main process that decides the diversity of proteins in our bodies. It is estimated that more than 90% of genes are alternatively spliced in humans and therefore this process affects all cellular properties. The function of the majority of splicing isoforms is not characterized yet. Numerous splicing isoforms have been associated with disease progression in recent years and there is much interest in understanding their contribution to pathogenesis and how this can be reversed.

a. Undergraduate:The Aga Khan University (AKU), 1992 M.B.B.S (MD) Medicine Medical College, Karachi - Pakistan b. Graduate: Dalhousie University, 2002 MSc Clinical School of Public Health, Halifax, Epidemiology Nova Scotia, Canada (Chair: Dr. David MacLean, PhD) Graduate School of Public Health 2005 Diploma Global Health University of Pittsburgh, Pittsburgh (Chair: Ron LaPorte, PhD) c. Postgraduate: College of Physicians & Surgeons 1996 FCPS Medicine Karachi- Pakistan

Dr. Zhengyuan Xia had served as a cardiovascular anesthetist for more than 10 years in China before he completed his Ph.D study at the University of British Columbia (UBC), in Canada in 2004 and postdoctoral studies at UBC and University of Calgary in 2007. He is Assistant Professor and Honorary Associate Professor at the University of Hong Kong, and his major focus of research is cardiac protection during ischemia-reperfusion in diabetes. He has published more than 65 papers in reputed journals and serving as an editorial board member of Journal of Diabetes & Metabolism.

Antioxidant treatments for myocardial ischemia-reperfusion injury Pharmacological (anesthetic) preconditioning and postconditioning Reactive oxygen species signalling in diabetic cardiomyophathy

Medical studies at the universities of Giessen, Kiel and Heidelberg Training in internal medicine at Enköping`s Hospital in Sweden (1970 1971) and at Mannheim, University of Heidelberg, 1974-1977.Studies in Epidemiology and Public Health at UCLA (MPH 1972) and UNC -Chapel Hill (PhD 1980)

Epidemiology and prevention of cardiovascular diseases, e.g., Munich Blood Pressure Study and Program, worldwide WHO MONICA project, PI MONICA Augsburg. Europe wide EUROASPIRE I, II, III project, member of the SCORE project. Member of the Scientific Advisory Committee, Association for the Mediterranean Diet: nutrition and lifestyle. Pioppi, Italy. Studies on active and pas sive smoking in Germany. Calculation of 3300 annual deaths from passive smoking in Germany in 2006.Epidemiology of asthma and allergies in childhood and adolescents, e.g. worldwide ISAAC project. Occupational epidemiology, e.g. studies in the American and German rubber industry.